The TRND program aims to encourage and speed the development of new treatments for rare and neglected diseases. The program is designed to advance the entire field of therapeutic development by encouraging scientific and technological innovations to improve success rates in the crucial preclinical stage of development.
TRND closes the gap that often exists between a basic research discovery and testing of new drugs in humans. That work includes the optimization and preclinical testing of therapies, with the goal to generate sufficient-quality data to support successful IND applications to the Food and Drug Administration and first-in-human studies in limited circumstances. Therapeutic clinical candidates that reach this stage should be attractive to biotechnology and pharmaceutical companies to take into clinical development.